PubMed Health⌕ Search

Biomedical subjects

Dong Liu

Publications and source records attributed to Dong Liu.

77 records · Page 5Linked to original sources

Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease.

The adult mammalian brain contains populations of stem cells that can proliferate and then differentiate into neurons or glia. The highest concentration of such neural progenitor cells (NPC) is located in the subventricular zone (SVZ) and these cells can produce new olfactory bulb and cerebral cortical neurons. NPC may provide a cellular reservoir for replacement of cells lost during normal cell turnover and after brain injury. However, neurogenesis does not compensate for neuronal loss in age-related neurodegenerative disorders such as Alzheimer's disease (AD), suggesting the possibility that impaired neurogenesis contributes to the pathogenesis of such disorders. We now report that amyloid beta-peptide (Abeta), a self-aggregating neurotoxic protein thought to cause AD, can impair neurogenesis in the SVZ/cerebral cortex of adult mice and in human cortical NPC in culture. The proliferation and migration of NPC in the SVZ of amyloid precursor protein (APP) mutant mice, and in mice receiving an intraventricular infusion of Abeta, were greatly decreased compared to control mice. Studies of NPC neurosphere cultures derived from human embryonic cerebral cortex showed that Abeta can suppress NPC proliferation and differentiation, and can induce apoptosis. The adverse effects of Abeta on neurogenesis were associated with a disruption of calcium regulation in the NPC. Our data show that Abeta can impair cortical neurogenesis, and suggest that this adverse effect of Abeta contributes to the depletion of neurons and the resulting olfactory and cognitive deficits in AD.

Amyloid beta-Peptides↗

Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders.

As in other cells, neurons use adenosine triphosphate (ATP) as an energy source to drive biochemical processes involved in various cell functions, and produce reactive oxygen species (ROS) as "by products" of oxidative phosphorylation. However, the electrical excitability and structural and synaptic complexity of neurons present unusual demands upon cellular systems that produce or respond to ATP and ROS. Mitochondria in axons and presynaptic terminals provide sources of ATP to drive the ion pumps that are concentrated in these structures to rapidly restore ion gradients following depolarization and neurotransmitter release. Mitochondria may also play important roles in the regulation of synaptic function because of their ability to regulate calcium levels and ROS production. ROS generated in response to synaptic activity are now known to contribute to the regulation of long-term structural and functional changes in neurons, and the best-known example is the nitric oxide radical. The high-energy demands of synapses, together with their high levels of ROS production, place them at risk during conditions of increased stress, which occur in aging, neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, and after acute traumatic and ischemic insults. Energy depletion and/or increased oxidative damage to various synaptic proteins can result in a local dysregulation of calcium homeostasis and synaptic degeneration. Accordingly, recent studies have shown that dietary and pharmacological manipulations that improve energy efficiency and reduce oxyradical production can prevent synaptic degeneration and neuronal death in experimental models of neurodegenerative disorders. A better understanding of the molecular control of subcellular energy production and utilization, and of the functional relationships between energy metabolism, ion homeostasis, and cytoskeletal and vesicular dynamics, will provide novel insight into mechanisms of neuronal plasticity and disease.

Adenosine Triphosphate↗

Triptolide inhibits proinflammatory factor-induced over-expression of class II MHC and B7 molecules in renal tubular epithelial cells.

AIM: To investigate the effects of triptolide on proinflammatory factor-induced over-expression of class II major histocompatibility complex (class II MHC), B7-1, B7-2, and intercellular adhesion molecule-1 (ICAM-1) in human proximal tubular epithelial (HKC) cells. METHODS: HKC cells were exposed to both interferon gamma (IFN-gamma, 200 microg/L) and tumor necrosis factor alpha (TNF-alpha, 20 microg/L) and cultured in media containing different concentrations of triptolide for 24 h. Class II MHC, B7-1, B7-2, and ICAM-1 levels in HKC cells were evaluated by flow cytometry. ICAM-1 mRNA level was measured by semi-quantitative RT-PCR method. RESULTS: HKC cells expressed quite high level of ICAM-1 and very low levels of class II MHC, B7-1, and B7-2 molecules. Class II MHC, B7-1, B7-2, and ICAM-1 levels in HKC cells were significantly increased by the costimulation of IFN-gamma and TNF-alpha. Triptolide inhibited the over-expression of class II MHC, B7-1, and B7-2 molecules in a concentration-dependent manner. The up-regulations of ICAM-1 molecules and ICAM-1 mRNA level were not altered by triptolide. CONCLUSION: Triptolide can significantly inhibit proinflammatory factors induced over-expression of class II MHC, B7-1, and B7-2 costimulatory factors in tubular epithelial cells. These results may contribute to the therapeutic effects of triptolide in some renal diseases.

Antigens, CD↗

Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model.

Recombinant mouse protein C was cloned, expressed, purified, and activated by Protac or thrombin. The anticoagulant activities of mouse and human activated protein C (APC) were compared using mouse and human plasma and the neuroprotective properties of murine APC were studied in an ischemic stroke model. Both human APC and mouse APC prolonged the activated partial thromboplastin time in a dose-dependent manner, but mouse APC was sixfold more effective than human APC as an anticoagulant in mouse plasma. Human protein S enhanced prolongation of the APTT clotting time of human plasma by human APC, but not by mouse APC. Hydrolysis of the S-2366 chromogenic substrate by murine APC was essentially identical to human APC. Mouse plasma contains 75 nM protein C. In a murine ischemic stroke model based on middle cerebral artery occlusion, murine APC was highly neuroprotective. The results show that recombinant murine APC is functionally similar to human APC both in vitro and in vivo and that it displays significant species specificity. The results imply that murine APC is notably superior to human APC for studies of murine disease models, including thrombosis and ischemic brain injury.

Animals↗